Hence expression changes in ESRP1 and ESRP2 in clinical prostate cancer disease progression, and downstream modulation of mRNA splicing patterns, most likely occur within the broader context of global changes taking place in the splicing environment [11, 53]. The gene discussed is ESRP2; the disease is prostate cancer.